Theriva Biologics, Inc. (SFY.F)
| Previous close | 0.2105 |
| Open | 0.2210 |
| Bid | 0.2120 x N/A |
| Ask | 0.2520 x N/A |
| Day's range | 0.2210 - 0.2210 |
| 52-week range | 0.2210 - 1.2800 |
| Volume | |
| Avg. volume | 107 |
| Market cap | 4.396M |
| Beta (5Y monthly) | N/A |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- GlobeNewswire
Theriva™ Biologics Announces Fast Track Designation Granted by the U.S. FDA for VCN-01 for the Treatment of Metastatic Pancreatic Cancer
ROCKVILLE, Md., May 23, 2024 (GLOBE NEWSWIRE) -- Theriva™ Biologics (NYSE American: TOVX), a diversified clinical-stage company developing therapeutics designed to treat cancer and related diseases in areas of high unmet need, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation (FTD) to lead clinical candidate VCN-01 in combination with gemcitabine and nab-paclitaxel to improve progression-free survival and overall survival in patients with metasta
- GlobeNewswire
Theriva™ Biologics to Participate in the A.G.P. Virtual Healthcare Conference
ROCKVILLE, Md., May 14, 2024 (GLOBE NEWSWIRE) -- Theriva™ Biologics (NYSE American: TOVX), a diversified clinical-stage company developing therapeutics designed to treat cancer and related diseases in areas of high unmet need, today announced that Company’s Management will provide a corporate update and participate in a fireside chat at the A.G.P. 2024 Virtual Healthcare Conference. A.G.P. 2024 Virtual Healthcare ConferenceFormat: Fireside Chat Presentation Date: Tuesday, May 21, 2024Presentatio
- GlobeNewswire
Theriva™ Biologics Reports First Quarter 2024 Operational Highlights and Financial Results
- Reported topline data from the investigator sponsored Phase 1 trial of intravitreal VCN-01 in pediatric patients with refractory retinoblastoma; trial results were determined to be positive by the study Monitoring Committee- -Presented preclinical data demonstrating the potential synergy between VCN-01 and liposomal irinotecan in a human pancreatic mouse xenograft at the ASGCT Annual Meeting; emphasizes VCN-01’s potential in diverse chemotherapy combinations for improved efficacy in pancreatic
